Zetina TH, Martínez GE, Calderón AM, Venegas ÁD, Rentería AMC, Méndez LR, Villaseñor CC

Language: Spanish
References: 21
Page: 151-155
PDF size: 53.61 Kb.

ABSTRACT

Objective: To report our experience on the perioperative management of cardiac surgery Jehovah’s Witnesses (JW). Design: Descriptive study. Setting: Postoperative ICU of a general hospital, Mexico City. Patients: Eleven Jehovah’s Witnesses (mean age 32.8 years, range 13-45 years) refusing transfusion of blood products were included. Interventions: A dose of 2,000 UI of recombinant human erythropoietin (r-HuEPO) were given a week before surgery and an additional dose of 2,000 UI 24 hours after surgery if a decrease ‹ 9 g/hemoglobin was occurred. Cell-saver system was used during the surgery. Measurements and main results: Length of cardiopulmonary bypass (CPB), length of aortic clamping (AoC), mortality, ICU stay 61.09 h (range 24-168 h), days of mechanical ventilation, (AMV) postoperative hemoglobin, bleeding an mortality were registered. Results: Length of CPB was 83.5’ (23-133’) AoC 45.5’ (range 9-92’), ICU stay 61.09 h (24-168 h) AMV 22.6 h (1-144 h), Hb 6.5 g/dL (4.3-9 g/dL, postoperative bleeding 410 mL. Cardiac failure 54.54%, pulmonary failure 18.18%, A-V block 09.09%, arterial hypertension 09.09%; a patient required surgery re-exploration. All the patients survived. Conclusion: In this preliminary report, the utilization of Cell-saver system and rHuEPO were useful in the management of cardiac surgery TJ.

REFERENCES

1. Spiess B. Coagulation dysfunction after cardiopulmonary bypass. In: Williams J, editor: Postoperative management of the cardiac surgery patients. 1a. ed. New York: Churchill Livingstone; 1996: 175-197.

2. Culkin Mann M, Votto J, Kambe J, McNamee M. Management of the severely anemic patient who refuses transfusion: Lessons learned during the care of a Jehovah’s Witness. Ann Int Med 1992; 117: 1042-8.

3. Rasche GE. Fluosol a special boon to Jehovah’s Witnesses. JAMA 1980; 243: 720-4.

4. Immovable for the right to worship. Watchtower 1945; 66: 195-6.

5. Green D, Handley E. Ann Int Med 1990; 113: 720-1.

6. Prince V. Commonwealth of Massachusetts. 19, 44; 321 U.S. 158.

7. Tawes R, Scribner R, Duval T et al. The Cell-saver and autologous transfusion: An underutilized resource in vascular surgery. Am J Surg 1986; 152: 105-7.

8. Koestner J, Nelson L, Morris J, Safcsak K. Use of Recombinant human erythropoietin (r-HuEPO) in a Jehovah’s Witness refusing transfusion of blood products: Case report. J Trauma 1990; 30: 1406-8.

9. Goodnough L, Monk T, Andriole G. Erythropoietin therapy. Current concepts. NEJM 1997; 336: 933-8.

10. Levine E, Gould S, Rosen A, Sehgal L, Egrie J, Sehgal H, Levine H, Moss G. Perioperative recombinant human erythropoietin. Surgery 1989; 106: 432-8.

11. Levine E, Rosen A, Sehgal L, Gould S, Egrie J, Sehgal H, Moss G. Treatment of acute postoperative anemia with recombinant human erythropoietin. J Trauma 1989; 29: 1134-8.

12. Zetina TH, Rentería AMC, Bonilla LC. Algoritmo para extubación temprana en pacientes posoperados de cirugía cardiaca. Rev Asoc Mex Med Crit y Ter Int 1998; I2: 49-53.

13. Carson J, Spence R, Poses R, Bonavita G. Severity of anaemia and operative mortality and morbidity. Lancet 1988: 727-9.

14. Levine E, Sehgal R, Sehgal H, Gould S, Moss G. Physiologic effects of acute anemia: Implications for a reduced transfusion trigger. Transfusion 1990; 30: 11-14.

15. Otto DA, Cooley DA. Cardiovascular surgery in Jehovah’s Witnesses Report of 542 operations without blood transfusion. JAMA 1977; 238: 1256-8.

16. Peterffy A, Horvath G, Tamas G, Bodnar F, Szokol M, Vasily M. Open Heart surgery in Jehovah’s Witnesses. Orv Hetil 2000; 141: 959-61.

17. Nearman H, Eckhauser ML. Postoperative management of a severely anemic Jehovah’s Witness. Crit Care Med 1983; 11(2): 142-43.

18. Martens P. Desmopressin and Jehovah’s Witness. Lancet 1989: 1322.

19. Salzman E, Weinstein M, Weintraub R, Ware J, Thurer R, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J, Smith M, Chute L. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. NEJM 1986; 314: 1402-6.

20. Spiess B, Gillies B, Chandler W, Verrier E. Changes in transfusion therapy and re-exploration rate after institution of a blood management program in cardiac surgical patients. J Cardiovasc & Vasc Anest 1995; 9: 168-73.

21. Gould S, Rosen A, Sehgal L, Sehgal H, Langdale L, Krause L, Rice C, Chamberlein W, Moss G. Fluosol-DA as a red-cell substitute in acute anemia. NEJM 1986; 314: 1653-6.